Alzheimer's disease and its treatment by different approaches: A review

被引:224
|
作者
Srivastava, Sukriti [1 ]
Ahmad, Razi [1 ]
Khare, Sunil Kumar [1 ]
机构
[1] Indian Inst Technol Delhi, Dept Chem, Enzyme & Microbial Biochem Lab, New Delhi 110016, India
关键词
Acetylcholinesterase; Alzheimer's disease; Amyloid beta protein; Biomarker; Clinical trial; Molecular target; Stem cell; Nanoparticle; NEURAL STEM-CELLS; MILD COGNITIVE IMPAIRMENT; SOLID-LIPID NANOPARTICLES; ENHANCED BRAIN DELIVERY; MARROW STROMAL CELLS; BINDING PROTEIN 43; VIRGIN OLIVE OIL; IN-VITRO; INDUCED PLURIPOTENT; GOLD NANOPARTICLES;
D O I
10.1016/j.ejmech.2021.113320
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mental ability development and interrupts neurocognitive function. This neuropathological condition is depicted by neurodegeneration, neural loss, and development of neurofibrillary tangles and Ab plaques. There is also a greater risk of developing AD at a later age for people with cardiovascular diseases, hypertension and diabetes. In the biomedical sciences, effective treatment for Alzheimer's disease is a severe obstacle. There is no such treatment to cure Alzheimer's disease. The drug present in the market show only symptomatic relief. The cause of Alzheimer's disease is not fully understood and the blood-brain barrier restricts drug efficacy are two main factors that hamper research. Stem cell-based therapy has been seen as an effective, secure, and creative therapeutic solution to overcoming AD because of AD's multifactorial nature and inadequate care. Current developments in nanotechnology often offer possibilities for the delivery of active drug candidates to address certain limitations. The key nanoformulations being tested against AD include polymeric nanoparticles (NP), inorganic NPs and lipid-based NPs. Nano drug delivery systems are promising vehicles for targeting several therapeutic moieties by easing drug molecules' penetration across the CNS and improving their bioavailability. In this review, we focus on the causes of the AD and their treatment by different approaches. (C) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Neuromodulation in the Treatment of Alzheimer's Disease: Current and Emerging Approaches
    Pople, Christopher B.
    Meng, Ying
    Li, Daniel Z.
    Bigioni, Luca
    Davidson, Benjamin
    Vecchio, Laura M.
    Hamani, Clement
    Rabin, Jennifer S.
    Lipsman, Nir
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2020, 78 (04) : 1299 - 1313
  • [32] GalantamineA Review of its Use in Alzheimer’s Disease
    Lesley J. Scott
    Karen L. Goa
    [J]. Drugs, 2000, 60 : 1095 - 1122
  • [33] RivastigmineA Review of its Use in Alzheimer’s Disease
    Caroline M. Spencer
    Stuart Noble
    [J]. Drugs & Aging, 1998, 13 : 391 - 411
  • [34] Hippocampus and its involvement in Alzheimer’s disease: a review
    Y. Lakshmisha Rao
    B. Ganaraja
    B. V. Murlimanju
    Teresa Joy
    Ashwin Krishnamurthy
    Amit Agrawal
    [J]. 3 Biotech, 2022, 12
  • [35] Hippocampus and its involvement in Alzheimer's disease: a review
    Rao, Y. Lakshmisha
    Ganaraja, B.
    Murlimanju, B., V
    Joy, Teresa
    Krishnamurthy, Ashwin
    Agrawal, Amit
    [J]. 3 BIOTECH, 2022, 12 (02)
  • [36] MetrifonateA Review of its Use in Alzheimer’s Disease
    Douglas Ormrod
    Caroline Spencer
    [J]. CNS Drugs, 2000, 13 : 443 - 467
  • [37] DonepezilA Review of its Use in Alzheimer’s Disease
    Mukta Dooley
    Harriet M. Lamb
    [J]. Drugs & Aging, 2000, 16 : 199 - 226
  • [38] Galantamine - A review of its use in Alzheimer's disease
    Scott, LJ
    Goa, KL
    [J]. DRUGS, 2000, 60 (05) : 1095 - 1122
  • [39] MemantineA Review of its Use in Alzheimer’s Disease
    Dean M. Robinson
    Gillian M. Keating
    [J]. Drugs, 2006, 66 : 1515 - 1534
  • [40] Metrifonate - A review of its use in Alzheimer's disease
    Ormrod, D
    Spencer, C
    [J]. CNS DRUGS, 2000, 13 (06) : 443 - 467